We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.25563 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Safety and Efficacy of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Deep Vein Thrombosis (DVT) Treatment: A Meta-analysis.
Cardiovasc Drugs Ther
December 2024
Vascular Surgery Department, General Surgery Center, First Hospital of Jilin University, Changchun City, Jilin Province, P.R. China.
Purpose: This meta-analysis aimed to conduct a systematic evaluation of the comparative efficacy and safety of new oral anticoagulants (NOACs) versus warfarin for the treatment of deep venous thrombosis (DVT).
Methods: A systematic computerized search of databases including PubMed, Medline, Web of Science, Embase, Cochrane Library, and www.
Clinicaltrials: gov .
Long-Term Safety and Efficacy of Lacosamide Combined with NOACs in Post-Stroke Epilepsy and Atrial Fibrillation: A Prospective Longitudinal Study.
J Pers Med
November 2024
Department of Stroke Unit, San Camillo-Forlanini Hospital, 00152 Rome, Italy.
Stroke is the leading cause of seizures and epilepsy in adults; however, current guidelines lack robust recommendations for treating post-stroke seizures (PSSs) and epilepsy (PSE). This study aims to demonstrate the long-term safety and efficacy of lacosamide combined with non-vitamin K antagonist oral anticoagulants (NOACs) in patients with PSE and atrial fibrillation (AF). In this prospective longitudinal single-center study, 53 patients with concomitant PSE and AF, admitted between 2022 and 2023, received NOACs for AF management and lacosamide for seizure control.
View Article and Find Full Text PDF[Risk factors of recurrence of acute ischemic stroke and construction of a nomogram model for predicting the recurrence risk based on Lasso Regression].
Nan Fang Yi Ke Da Xue Xue Bao
December 2024
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Objectives: To investigate the risk factors of recurrence of acute ischemic stroke (AIS) within 1 year and establish a nomogram model for predicting the recurrence risk.
Methods: This study was conducted in two cohorts of AIS patients (≤7 days) hospitalized in Dongzhimen Hospital (modeling set) and Fangshan Hospital (validation set) from March, 2021 to March, 2022. Lasso regression analysis was used to identify the important predictive factors for AIS recurrence within 1 year, and multivariate Logistic regression analysis was performed to analyze the independent factors affecting AIS recurrence.
Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents.
Front Oncol
December 2024
Department of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Article Synopsis
- Primary liver cancer, mainly hepatocellular carcinoma (HCC), is a major cause of cancer deaths, and tumor thrombus (TT) in major vessels worsens patient outcomes.
- Four male HCC patients (average age 57) with TT in the inferior vena cava or right atrium underwent surgery to remove the tumors, followed by targeted and immunotherapy.
- All cases show positive outcomes post-treatment, with some patients remaining disease-free for up to 74 months, suggesting that combining surgery with therapy could improve survival rates in advanced HCC patients.
Fractional flow reserve-guided complete revascularization versus culprit-only percutaneous coronary intervention in patients with myocardial infarction: A meta-analysis of randomized controlled trials.
Cardiovasc Revasc Med
December 2024
Department of Cardiovascular Medicine, Baystate Medical Center and Division of Cardiovascular Medicine, University of Massachusetts-Baystate, Springfield, MA, USA. Electronic address: https://twitter.com/AGoldsweig.
Introduction: The optimal revascularization strategy for patients with myocardial infarction (MI) and multivessel coronary artery disease (CAD) remains an area of research and debate. Fractional flow reserve (FFR)-guided complete revascularization (CR) by percutaneous coronary intervention (PCI) has emerged as an alternative to traditional culprit-only PCI.
Objective: To investigate the outcomes of FFR-guided CR versus culprit-only PCI in patients with MI and multivessel CAD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!